Entry Point Capital, LLC Avidity Biosciences, Inc. Put Options Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding RNA
# of Institutions
213Shares Held
95.5MCall Options Held
171KPut Options Held
196K-
Price T Rowe Associates Inc Baltimore, MD10.9MShares$472 Million0.05% of portfolio
-
Rtw Investments, LP New York, NY8.81MShares$381 Million6.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$373 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.51MShares$281 Million3.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.94MShares$257 Million0.0% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $2.25B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...